David Kaysen named President and CEO of Sun BioPharma

He brings more than 25 years of healthcare, commercial and public company experience to the firm

Sun BioPharma, a biopharmaceutical company developing therapies for the treatment of pancreatic cancer, has appointed David Kaysen as President and Chief Executive. He has also joined the company's board of directors.

Kaysen brings to Sun BioPharma more than 25 years of healthcare clinical development, commercial and public company achievements. He joins the company as its lead development candidate, SBP-101, is expected to begin a Phase 1 clinical trial in Australia by the end of this year for the treatment of pancreatic cancer.

Prior to joining Sun, Kaysen was an advisor and senior executive to several domestic and European privately held healthcare companies. From 2006 to 2013 he was President and Chief Executive of Uroplasty, a global medical device company that is now part of Cogentix Medical. Before this he was President and CEO of Advanced Duplications Services; President, Chief Executive and a director of Diametrics Medical and President, Chief Executive and a director of Rehabilicare.

You may also like

Packaging

Innovating primary packaging for parenteral drugs: challenges and future directions

The new challenges brought about by the pandemic call for an increasingly scientific approach to the evolution of single packaging elements in order to anticipate the needs of new drug formulations and guarantee a more enhanced, measurable and stable level of performance
Regulatory

US Pharmacopeia details mass spectrometry guidelines to advance biologics impurity control

The new chapter aims to standardise the use of mass spectrometry-based analysis in the biopharmaceutical industry, which can be used to detect impurities in cell and gene therapies, antibodies and other biologics
You need to be a subscriber to read this article.
Click here to find out more.
Research & Development

Hybrid interferons: developing a novel drug class

With many hurdles to overcome, establishing a new drug candidate is a long process — particularly if you are a smaller biotech company with limited resources. These challenges can be further amplified if the candidate being developed is of an entirely novel drug class
Packaging

How pharma packaging manufacturers role is evolving: the case of extractables testing

As the pharmaceutical industry continues to grow and evolve, extractables testing is a critical component of the pharmaceutical industry's efforts to prioritise quality and safety, ensuring one of the key functions pharma containers are designed for, says Anna Malori, Head of Product Management at Bormioli Pharma
Distribution

2BScientific expands its life science product supply service to Europe with new German facility

The facility in Munich will serve the European market with life science products, including in vitro diagnostic (IVD) reagents, buffers, biomaterials and antibodies
Manufacturing

Anton Paar expands Litesizer DIA Series with new models

Introducing affordable and advanced solutions for particle analysis
Manufacturing

Triple your efficiency with the new DrySyn Vortex

Boost productivity with temperature-controlled parallel reactions
Subscribe now